XNW-1011 is under clinical development by SinoMab Bioscience and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XNW-1011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XNW-1011 overview

XNW-1011 is under development for the treatment of B-cell malignancies including relapsed and refractory chronic lymphocytic leukemia / small cell lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom macroglobulinemia, diffuse large B-cell lymphoma, rheumatoid arthritis, pemphigus, neuromyelitis optica spectrum disorder, SLE and Chronic kidney disease (renal diseases). It is administered through oral route and formulated in the form of capsule. The drug candidate acts by targeting Bruton’s tyrosine kinase (BTK) and a new chemical entity (NCE).

SinoMab Bioscience overview

SinoMab Bioscience (SinoMab) is a biopharmaceutical company that provides manufacturing and therapeutics for the treatment of immunological diseases. The company offers products that include drugs such as SM03 for the treatment of rheumatoid arthritis. SinoMab’s pipeline products includes SM03, SM17, SM06, SM09 and TMF2. It also offers clinical trails to treat rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin’s lymphoma, asthma, and other diseases with major unmet clinical needs. The company also has research and development center and in-house manufacturing to extend the market. Its manufacturing facility is located in Haikou, Hainan, China. SinoMab is headquartered in New Territories, Hong Kong.

For a complete picture of XNW-1011’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.